- Home
- GILD vs VRTX Comparison
GILD vs VRTX Comparison
Compare GILD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- VRTX
- Stock Information
- Founded
- GILD 1987
- VRTX 1989
- Country
- GILD United States
- VRTX United States
- Employees
- GILD N/A
- VRTX N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- VRTX EDP Services
- Sector
- GILD Health Care
- VRTX Technology
- Exchange
- GILD Nasdaq
- VRTX Nasdaq
- Market Cap
- GILD 129.9B
- VRTX 115.6B
- IPO Year
- GILD 1992
- VRTX 1991
- Fundamental
- Price
- GILD $110.08
- VRTX $442.05
- Analyst Decision
- GILD Buy
- VRTX Buy
- Analyst Count
- GILD 25
- VRTX 26
- Target Price
- GILD $109.00
- VRTX $512.54
- AVG Volume (30 Days)
- GILD 8.8M
- VRTX 2.2M
- Earning Date
- GILD 04-24-2025
- VRTX 05-05-2025
- Dividend Yield
- GILD 2.87%
- VRTX N/A
- EPS Growth
- GILD 1118.07
- VRTX N/A
- EPS
- GILD 4.73
- VRTX N/A
- Revenue
- GILD $28,735,000,000.00
- VRTX $11,099,700,000.00
- Revenue This Year
- GILD $1.54
- VRTX $10.36
- Revenue Next Year
- GILD $3.70
- VRTX $10.61
- P/E Ratio
- GILD $23.27
- VRTX N/A
- Revenue Growth
- GILD 4.68
- VRTX 8.98
- 52 Week Low
- GILD $62.07
- VRTX $377.85
- 52 Week High
- GILD $119.96
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- GILD 58.78
- VRTX 43.63
- Support Level
- GILD $107.23
- VRTX $427.43
- Resistance Level
- GILD $109.55
- VRTX $451.64
- Average True Range (ATR)
- GILD 2.90
- VRTX 10.29
- MACD
- GILD 1.01
- VRTX 2.22
- Stochastic Oscillator
- GILD 90.02
- VRTX 72.63
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.